Home » Stocks » BHVN

Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)

Stock Price: $84.91 USD -6.84 (-7.46%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $84.40 -0.51 (-0.60%) Jan 15, 7:40 PM
Market Cap 5.11B
Revenue (ttm) 28.51M
Net Income (ttm) -410.44M
Shares Out 59.68M
EPS (ttm) -12.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $84.91
Previous Close $91.75
Change ($) -6.84
Change (%) -7.46%
Day's Open 91.24
Day's Range 84.47 - 92.39
Day's Volume 580,642
52-Week Range 27.51 - 98.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% inter...

Zacks Investment Research - 1 week ago

Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.

PRNewsWire - 1 week ago

NEW HAVEN, Conn., Jan. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical tri...

Zacks Investment Research - 2 weeks ago

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

PRNewsWire - 1 month ago

NEW HAVEN, Conn., Dec. 16, 2020 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that The Lancet published the company's positive results from a Phase...

Seeking Alpha - 1 month ago

Biohaven is establishing a comprehensive suite of migraine medicines. The company has an exciting pipeline of interesting late stage products.

PRNewsWire - 1 month ago

MOORESVILLE, N.C., Dec. 2, 2020 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing e...

PRNewsWire - 1 month ago

TOKYO and CAMBRIDGE, England, Dec. 1, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with B...

Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: COTY, DHR, FL, BH, STOK
CNBC - 1 month ago

"I hope that in six months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine," Biohaven CEO Vlad Coric said.

CNBC Television - 1 month ago

Biohaven Pharmaceutical CEO on efforts to prevent migraine with oral CGRP

CEO Vlad Coric said Biohaven, a biotech firm with a new product to treat migraines, plans to have a drug that can prevent migraines in the next sixth months.

PRNewsWire - 2 months ago

NEW HAVEN, Conn., Nov. 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-sta...

PRNewsWire - 2 months ago

NEW HAVEN, Conn., Nov. 11, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-...

Zacks Investment Research - 2 months ago

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Seeking Alpha - 2 months ago

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

  Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results.

Zacks Investment Research - 2 months ago

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 2 months ago

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Other stocks mentioned: ACAD, ALNY, AVRO, BNTX
PRNewsWire - 2 months ago

NEW HAVEN, Conn., Oct. 30, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-sta...

Insider Monkey - 2 months ago

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...

Zacks Investment Research - 3 months ago

Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.

PRNewsWire - 3 months ago

NEW HAVEN, Conn., Oct. 14, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepte...

PRNewsWire - 4 months ago

NEW HAVEN, Conn., Sept. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Investors Business Daily - 4 months ago

A Relative Strength Rating upgrade for BiohavenPharmaHldg shows improving technical performance.

Seeking Alpha - 4 months ago

Biohaven Is Still A Bargain On Increasing Nurtec ODT Sales

Seeking Alpha - 5 months ago

Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.

PRNewsWire - 5 months ago

NEW HAVEN, Conn., Aug. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

PRNewsWire - 5 months ago

NEW HAVEN, Conn., Aug. 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

PRNewsWire - 5 months ago

Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications

Other stocks mentioned: RPRX
PRNewsWire - 5 months ago

NEW HAVEN, Conn., Aug. 3, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

PRNewsWire - 5 months ago

NEW HAVEN, Conn., July 21, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Benzinga - 6 months ago

Biohaven Pharmaceutical Holding Co. Ltd.'s (NYSE: BHVN) "Nurtec ODT" drug will be promoted by media personality Khloe Kardashian, the company announced Wednesday.

CNBC - 6 months ago

Khloe Kardashian is working with Biohaven Pharmaceuticals to promote its newly launched migraine drug, Nurtec ODT.

CNBC Television - 6 months ago

Biohaven CEO on teaming with Khloé Kardashian on new migraine campaign

Biohaven Pharmaceuticals CEO Vlad Coric discussed launching Nurtec ODT, a drug to combat migraines, and what inspired celebrity Khloé Kardashian to get on board.

Investors Business Daily - 6 months ago

Biohaven Pharmaceutical delivered mixed results for its OCD treatment test on Wednesday — leading BHVN stock to tumble. Biohaven studied a drug called troriluzole in OCD patients.

PRNewsWire - 7 months ago

NEW HAVEN, Conn., June 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that it presented data from 25 accepted abstracts demonstrating the e...

PRNewsWire - 7 months ago

NEW HAVEN, Conn., June 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of pharmaceutical industry leader Robert J. Hugin to ...

The Motley Fool - 7 months ago

A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.

PRNewsWire - 7 months ago

NEW HAVEN, Conn., May 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the...

Seeking Alpha - 8 months ago

Biohaven Pharmaceutical Offers Good Value With Nurtec ODT Now On The Market

Zacks Investment Research - 8 months ago

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

InvestorPlace - 8 months ago

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: ATRA, CBAY, MRNS, PTCT, SLDB, TBIO
CNBC Television - 9 months ago

Biohaven CEO says new migraine treatment is a 'game changer for patients'

Biohaven CEO Vlad Coric discusses Nurtec ODT, the pharmaceutical company's newly launched oral tablet for migraines, and the importance of listening to patients.

The Motley Fool - 10 months ago

The drug enters a crowded market -- but it has a convenient format.

Seeking Alpha - 10 months ago

Meta-Analysis Suggested That Biohaven Pharmaceutical's Migraine Prevention Trial Is Highly Likely To Succeed

The Motley Fool - 11 months ago

Biohaven’s shares dropped after a failed clinical trial, and risk-tolerant investors are snapping them up.

The Motley Fool - 11 months ago

The company's candidate troriluzole failed to meet its primary endpoint in a trial as a treatment for generalized anxiety disorder.

Investors Business Daily - 11 months ago

Shares of Biohaven Pharmaceutical tumbled Monday after its drug, troriluzole, failed to pass muster as an anxiety medicine. The biotech is still testing troriluzole in three other diseases.

Market Watch - 11 months ago

Shares of Biohaven Pharmaceutical Holding Company Ltd. BHVN, -5.18% tumbled 16% in premarket trading on Monday after the company said its experimental treatment for generalized anxiety disorde...

About BHVN

Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The compan... [Read more...]

Industry
Biotechnology
IPO Date
May 4, 2017
CEO
Vlad Coric
Employees
647
Stock Exchange
NYSE
Ticker Symbol
BHVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for BHVN is 97.73, which is an increase of 15.10% from the latest price.

Price Target
$97.73
(15.10% upside)